drugset
drugset / Trial / NCT03995147

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

NCT03995147 ↗

Phase 2 Active not recruiting 51 enrolled University of Chicago Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.

Timeline

Start
2019-08-29
Primary completion
2027-02-20
Completion
2027-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Cyclophosphamide Other / unclassified — —
Background Doxorubicin Other / unclassified — —
Background Prednisone Other / unclassified — —
Background Rituximab Monoclonal antibody — —
Background Vincristine Small molecule — —

Indications

high grade B-cell lymphoma